Packed Red Blood Cells

Phase 1Small molecule

NNYU Langone Health

Packed Red Blood Cells is one of 69 small molecule programs targeting Cardiac Arrest. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

Cardiogenic ShockRecruiting

Cardiac ArrestPhase 1

Active, not recruiting

Iron Deficiency AnemiaPreclinical

Active, not recruiting

Cardiogenic ShockPhase 1

Recruiting

Competition

Competitive Landscape

89 competitors in Cardiac Arrest

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

1 2

Tofranil

Sanofi

Phase 3

1 3

Cordarone

WWyeth-Lederle Vaccines

Phase 3

6 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

—5

Esmeron

FFresenius Kabi Oncology Ltd.

Phase 3

3 6

Decadron

AAspen Global Incorporated

Phase 3

1 7

Pitressin

AAultman Health Foundation

Phase 3

1 8

Zyprexa

MMODAG GmbH

Phase 3

1 9

Xylocaine

MMEDRx USA, Inc.

Phase 3

1 10

Mexitil

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalNot yet recruiting

Bleeding

NCT07677150

Q4 2028

Phase 1Recruiting

Cardiogenic Shock

NCT05699005

Clinical

Trials by Indication[1]

Blood Pressure1 trial

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

Iron deficiency anemia1 trial

IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

Completed·TTexas Tech University Health Sciences Center, El Paso··NCT05153278·130 enrolled

Cardiac Arrest1 trial

Packed Red Blood Cell Transfusion During Cardiac Arrest

Recruiting·NNYU Langone Health·Phase 1·NCT06462027·30 enrolled

Cardiogenic Shock1 trial

Comparison of an Individualized Transfusion Strategy to a Conventional Strategy in Patients Undergoing Peripheral Veno-arterial ECMO for Refractory Cardiogenic Shock: a Randomized Controlled Trial - ICONE

Recruiting·UUniversity Hospital, Lille·Phase 1·NCT05699005·236 enrolled

Bleeding1 trial

Efficacy of Hemoglobin Oxygen Transport in Patients Receiving Intraoperative Cell Salvage vs. Packed Red Blood Cell Units - a Randomized Controlled Pilot Trial

Not yet recruiting·MMedical University Innsbruck·Preclinical·NCT07677150·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Packed Red Blood Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Packed Red Blood Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Packed Red Blood Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNYU Langone Health

Packed Red Blood Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Blood Pressure1 trial

Iron deficiency anemia1 trial

Cardiac Arrest1 trial

Cardiogenic Shock1 trial

Bleeding1 trial

References

Drug Info

Quick Facts

Related News